Shots: Novartis to get minority equity in Anthos and will grant rights to Anthos for MAA868 to develop in CVD. Blackstone Life Sciences to fund the joint venture with $250M […]readmore
Tags : Novartis
Shots: Novartis & Target PharmaSolutions collaborates for the onset of global TARGET-DERM study evaluating adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs) The initial focus of the collaboration […]readmore
Shots: Akcea to receive $150M as option license fee with equal sharing with Ionis as equity investment in Akcea. Novartis to get exclusive WW development and commercialization rights for Akcea’s […]readmore
Shots: AbCellera to receive technology access fee, funding, milestones, and royalties on sales of products. Novartis to get rights to license AbCellera’s technology for its 10 unknown targets Additionally, AbCellera […]readmore
Shots: Novartis to receive $210M as total deal value, including $120M upfront, $60M deferred payment for 12mos. and $30M milestone on sales of product. Clinigen to get commercialization rights for […]readmore
Shots: The approval is based on the study assessing Egaten (triclabendazole) in patients with fascioliasis aged ≥ 6yrs. Novartis’ Egaten is in use since 2005 by WH, serving 2M fascioliasis […]readmore
Shots: The approval is based on the P-II JULIET (NCT02445248) trial results assessing Kymriah (tisagenlecleucel) in patients with 1L+ DLBCL and followed by NICE approval in for pediatric and aged […]readmore
Shots: Philogen collaborates with J&J to discover & develop therapies utilizing Philochem’s technology (a Swizz subsidiary of Philogen) for serious conditions Philogen signs a development and commercialization agreement with Celgene […]readmore
Regulatory
Novartis’s SEG101(crizanlizumab) Receives FDA’s Breakthrough Therapy(BT) Designation for Sickle Cell
Shots: The BTD is based on P-II SUSTAIN study results assessing crizanlizumab (5 mg/kg) vs PBO in patients with/without hydroxyurea therapy for preventing vaso-occlusive crises(VOCs) in SCD P-II SUSTAIN study […]readmore
Shots: The approval is based on trial results assessing Xolair IV (q2w or q4w) in 1M patients with SAA and CSU for 13 years The study demonstrated in reduction of severe exacerbations, corticosteroid […]readmore